Literature DB >> 24389180

Bone marrow stromal cells in the pathogenesis of acute myeloid leukemia.

Olga Blau1.   

Abstract

Acute myeloid leukemia (AML) is clonal disorder affecting pluripotent stem cell and characterized by ineffective hematopoiesis. Genetic abnormalities in a progenitor cells is thought to lead to uncontrolled growth of leukemia cells. In addition, in the last years, it has been clearly recognized that the hematopoietic microenvironment (HM) plays an important role in the pathogenesis of AML. The HM can regulate hematopoiesis by interacting directly with HC and/or by secreting regulatory molecules that exert a positive or negative influence on the growth of HC. Stromal elements are important in the homing of immature HC or hematopoietic stem cells. Several studies propose that important quantitative and functional alterations are present in the BMSC of AML patients. AML may arise in the setting of an abnormal HM, resulting in the generation of multiple populations with varying initiation event. Dysfunction of HM may contribute to leukemia by supplying abundant growth factors that promote proliferation and/or inhibit apoptosis. Recent discoveries utilizing mouse models showed that genetic alteration in cells of HM can induce AML.

Entities:  

Mesh:

Year:  2014        PMID: 24389180     DOI: 10.2741/4203

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  6 in total

1.  Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia.

Authors:  Tibor J Kovacsovics; Alice Mims; Mohamed E Salama; Jeremy Pantin; Narayanam Rao; Ken M Kosak; Peter Ahorukomeye; Martha J Glenn; Michael W N Deininger; Kenneth M Boucher; Linda M Bavisotto; Gerardo Gutierrez-Sanchez; Thomas P Kennedy; Stephen G Marcus; Paul J Shami
Journal:  Blood Adv       Date:  2018-02-27

2.  miR-126 promotes the growth and proliferation of leukemia stem cells by targeting DNA methyltransferase 1.

Authors:  Qian Ding; Qing Wang; Yi Ren; Hongqian Zhu; Zhujun Huang
Journal:  Int J Clin Exp Pathol       Date:  2018-07-01

3.  A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes.

Authors:  Eric Huselton; Michael P Rettig; Theresa Fletcher; Julie Ritchey; Leah Gehrs; Kyle McFarland; Stephanie Christ; William C Eades; Kathryn Trinkaus; Rizwan Romee; Shashikant Kulkarni; Armin Ghobadi; Camille Abboud; Amanda F Cashen; Keith Stockerl-Goldstein; Geoffrey L Uy; Ravi Vij; Peter Westervelt; John F DiPersio; Mark A Schroeder
Journal:  Leuk Lymphoma       Date:  2021-01-19

4.  Multiple myeloma cells alter the senescence phenotype of bone marrow mesenchymal stromal cells under participation of the DLK1-DIO3 genomic region.

Authors:  Rimma Berenstein; Olga Blau; Axel Nogai; Marlies Waechter; Ekaterina Slonova; Martin Schmidt-Hieber; Annegret Kunitz; Antonio Pezzutto; Bernd Doerken; Igor Wolfgang Blau
Journal:  BMC Cancer       Date:  2015-02-18       Impact factor: 4.430

5.  Treatment of the bone marrow stromal stem cell supernatant by nasal administration-a new approach to EAE therapy.

Authors:  Xi Wang; Wantong Zhai; Jiahui Zhu; Wei Zhao; Xiaoyi Zou; Siying Qu; Shenyue Wang; Zhongze He; Zhaoying Li; Lingyang Wang; Bo Sun; Hulun Li
Journal:  Stem Cell Res Ther       Date:  2019-11-15       Impact factor: 6.832

6.  Stem Cell Mobilization with G-CSF versus Cyclophosphamide plus G-CSF in Mexican Children.

Authors:  José Eugenio Vázquez Meraz; José Arellano-Galindo; Armando Martínez Avalos; Emma Mendoza-García; Elva Jiménez-Hernández
Journal:  Stem Cells Int       Date:  2016-01-06       Impact factor: 5.443

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.